SGPL completes pharma transition

June 29, 2026 (MLN): S.G. Power Limited (PSX: SGPL) has completed the requisite corporate and regulatory formalities relating to a change in its principal line of business, transitioning from Power Generation Allied (Other) to Pharmaceutical Allied (Healthcare Sector).

Following the approval of members through a Special Resolution passed at an Extraordinary General Meeting held on May 13, 2026, and the subsequent registration of the relevant statutory filings with the Securities and Exchange Commission of Pakistan (SECP), the change in principal line of business has been formally effected.

The amended principal line of business authorizes the company to undertake the import, export, manufacture, distribution, marketing, sale, rental, installation, maintenance and after-sales servicing of medical equipment, medical devices, hospital supplies and related healthcare products, together with the manufacture and trading of pharmaceutical, medicinal and allied products, as set out in the amended Memorandum of Association.

The company is also currently undertaking the requisite corporate and regulatory processes for a change of name to more accurately show its revised business focus and operational activities.

Upon completion of the name change process and the incorporation of all consequential amendments and approvals, the Pakistan Stock Exchange and all relevant stakeholders will be duly notified.

The company views the development as a significant milestone in its strategic transformation, establishing the regulatory framework for pursuing opportunities within Pakistan's healthcare and pharmaceutical sectors.

The aforementioned information was disseminated through a notification to Exchange.

Copyright Mettis Link News